EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions



Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions



American Journal of Cardiology 86(Suppl 8A): 15i, October 16




(PDF 0-2 workdays service: $29.90)

Accession: 035349981

Download citation: RISBibTeXText



Related references

Prospective randomized comparison of enoxaparin versus unfractionated heparin for elective percutaneous coronary interventions among ticlopidine-pretreated patients. European Heart Journal 21(Abstract Supplement): 381, August-September, 2000

Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS). Eurointervention 6(3): 407-412, 2011

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. Journal of the American College of Cardiology 28(6): 1437-1443, 1996

Low molecular weight heparin in percutaneous transluminal coronary angioplasty Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial. Journal of the American College of Cardiology 28(6): 1437-1443, 1996

A randomized comparison of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Journal of the American College of Cardiology 41(6 Supplement A): 68A-69A, March 19, 2003

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. Jacc. Cardiovascular Interventions 2(11): 1083-1091, 2010

The Essence Trial: Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave MI: A Double-Blind, Randomized, Parallel-Group, Multicenter Study Comparing Enoxaparin and Intravenous Unfractionated Heparin: Methods and Design. Journal of Thrombosis and Thrombolysis 4(2): 271-274, 1997

Use of a combination of enoxaparin or unfractionated heparin and abciximab during percutaneous coronary interventions: a randomized pilot study. Revista Espanola de Cardiologia 55(12): 1261-1266, 2002

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE Trial). Journal of the American College of Cardiology 28(6): 1437-1443, 1996

Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. American Heart Journal 144(3): 470-477, 2002

A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis 76(4): 529-534, 1996

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. Journal of the American College of Cardiology 36(3): 693-698, 2000

Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. American Heart Journal 144(3): 470-477, September, 2002

Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL Trial. Angiology 68(1): 29-39, 2016

A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. American Heart Journal 151(1): 175-175, 2005